SABIO HOLDINGS INC.

SAB BIO presented updates on SAB-142 at the Citigroup conference: the SAFEGUARD study is progressing as planned with more than 60 activated sites, full enrollment expected in Q4 2026 and top-line data in the second half of 2027. The company has $208 million in cash, expected to fund operations through the end of 2028, and estimates the U.S. market potential for SAFEGUARD-eligible patients conservatively at around $4 billion. SAB-142 is differentiated by a shorter infusion regimen and a repeat-dosing model; a follow-up study (PRIZE) is planned to extend the indication beyond the first 100 days. Approval will continue to depend on clinical evidence; accelerated approval using C-peptide as a surrogate remains a possible alternative. » More on de.investing.com

Sabio Holdings reported a Q2 2026 EPS loss of $0.07 (expectation -$0.02) and revenue of $8.23 million, well below estimates of $11.9 million. Gross margin improved to 61% and the programmatic business showed strong growth (US +240%, EMEA +386%), which reduced the adjusted EBITDA deficit. Management expects positive adjusted EBITDA in H2 2026 supported by >$2 million in annual cost savings, policy/lobby commitments of $5 million, and continued programmatic growth. Cash on hand was $1.5 million; the stock rose moderately 5% to $0.11 after the results. » More on de.investing.com